Imagine a life-saving treatment for a rare but deadly complication of a common diabetes medication, yet many hospitals aren't using it. That's the stark reality of metformin-associated lactic acidosis (MALA), a condition where the body dangerously accumulates lactic acid. But here's where it gets groundbreaking: researchers have developed a protocol that significantly reduces mortality rates and speeds up treatment. Their findings, to be unveiled at ASN Kidney Week 2025 (November 5–9), could revolutionize how we manage this critical condition.
This innovative protocol, implemented at Maharat Nakhonratchasima Hospital (MNRH) in Thailand, focuses on immediate dialysis initiation using various methods: intermittent hemodialysis, continuous kidney replacement therapy, or peritoneal dialysis. In contrast, Burirum Hospital (BH) did not adopt this approach. Over five years, 347 cases were analyzed (70 pre-intervention at MNRH, 129 during intervention at MNRH, and 148 at BH).
The results are striking. At MNRH, the 30-day mortality rate plummeted from 25.7% to 13.9% after the protocol was introduced, while BH saw no improvement, with rates hovering around 27-30%. This raises a critical question: Why aren’t more hospitals adopting this life-saving protocol? The data from MNRH also showed a consistent quarterly decrease in mortality rates (-2.08%) during the intervention period. Additionally, the average door-to-dialysis time—a crucial factor in MALA treatment—was slashed from 870 minutes to 690 minutes. Awareness of MALA among healthcare providers at MNRH surged from 38.5% to 89.9%, highlighting the importance of education in improving patient outcomes.
The protocol’s success lies in its standardization, covering diagnosis, access to treatment, and care delivery. By streamlining processes, it minimizes delays and reduces variability in treatment. But here’s the controversial part: despite its proven benefits, the protocol isn’t widely adopted. Is it due to lack of awareness, resource constraints, or resistance to change? Fast-track dialysis pathways, as demonstrated in MNRH, are essential for time-sensitive conditions like MALA. Ensuring access to all dialysis modalities provides the flexibility needed for prompt treatment initiation.
Watanyu Parapiboon, MD, the corresponding author from MNRH, emphasizes the protocol’s potential to save lives. However, its implementation requires broader acceptance and support from healthcare institutions worldwide. What do you think? Should this protocol become the standard of care for MALA? Share your thoughts in the comments below.
Source: [Insert Source Here]
Disclaimer: While this content is based on edited and approved material, it may occasionally contain inaccuracies. Always verify medical information with relevant suppliers or authors. This article does not provide medical advice; consult a healthcare professional for personalized guidance.
